ENTRADA THERAPEUTICS INCTRDA
ASignal's systematic analysis rates TRDA as Neutral.
Reflects the latest available analysis · analyzed Oct 11, 2026
The case on TRDA
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- RSI indicates potential oversold condition (29.36)
- Strong liquidity position with current ratio of 10.89x
- Low debt-to-equity ratio of 0.21x
- High cash reserves of $223.00M
- Negative MACD histogram and MACD below signal line
- Price below both SMA20 and SMA50 indicating downtrend
- Negative price momentum (-0.088)
- Negative operating margin (-5007.02%)
- Negative return on equity (-54.10%)
- Negative free cash flow (-$77.67M)
See the full verdict on TRDA
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes TRDA
Most investors never get a second opinion, let alone several. ASignal runs TRDA past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.